Xbrane Estimates Q1 2023 Resubmission For US Lucentis Biosimilar
FDA Pushed Back On Initial BLA Filing Earlier This Year
Having first expected to resubmit the filing by the end of this year, a delay to a key report means Xbrane now expects to deliver its new biologics license application to the FDA during Q1 2023.
